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Purpose: Intimal hyperplasia and graft thrombosis are major causes of graft failure. Heparin prolongs graft patency and
inhibits neointimal hyperplasia in animal models. The purpose of this study was to evaluate the effect of a heparin-coated
expanded polytetrafluoroethylene (ePTFE) graft on platelet deposition and anastomotic neointimal hyperplasia after
aortoiliac bypass grafting in a baboon model.
Methods: Heparin-coated ePTFE grafts (4-mm diameter) were incorporated into exteriorized femoral arteriovenous
shunts placed in five baboons. Platelet deposition was analyzed by measuring the accumulation of indium 111–labeled
platelets on the grafts, with dynamic scintillation camera imaging. Eight adult male baboons (mean weight, 9.3 kg)
underwent bilateral aortoiliac bypass grafting with ePTFE grafts (4-mm internal diameter). In each animal a heparin-
coated ePTFE graft was placed in one aortoiliac artery, and an uncoated graft, which served as the control, was placed in
the contralateral aortoiliac artery. All grafts were harvested at 4 weeks, and were analyzed quantitatively for neointimal
hyperplasia at graft-vessel anastomoses.
Results: Early platelet deposition on heparin-coated grafts after 1 to 4 hours of ex vivo circuitry was significantly reduced.
All the harvested aortoiliac grafts were patent at 4 weeks. There was a significant reduction in neointimal area at both
proximal (0.26  0.11 mm2) and distal (0.29  0.14 mm2) anastomoses in the heparin-coated grafts, compared with
proximal (0.56  0.18 mm2) and distal (0.63  0.21 mm2) anastomoses in the untreated control grafts (P < .05). In
addition, neointimal cell proliferation assayed with bromodeoxyuridine (BrdU) incorporation was reduced in the graft
neointima (3.47%  0.43%) in heparin-coated grafts compared with the graft neointima (6.21%  0.59%) in untreated
control grafts (P < .05).
Conclusions: Small-caliber heparin-coated ePTFE grafts significantly reduce platelet deposition and anastomotic neoin-
timal hyperplasia and cell proliferation, without measurable side effects, in baboons. Surface coating with heparin in
small-caliber ePTFE grafts is useful for improving prosthetic bypass graft patency. (J Vasc Surg 2004;39:1322-8.)
Clinical Relevance: An autologous vein graft is the ideal bypass conduit in peripheral arterial reconstruction; however,
many patients who undergo bypass grafting do not have adequate or available autologous vein graft. As a result surgeons
often must rely on prosthetic grafts as an alternative conduit in arterial bypass procedures. Clinical outcomes with
prosthetic grafts in peripheral arterial reconstruction are generally inferior to those with autologous vein bypass grafts,
in part because of anastomotic neointimal hyperplasia. This study evaluated the effect of small-caliber heparin-coated
expandable polytetrafluoroethylene (ePTFE) grafts in aortoiliac reconstruction in a baboon model. The study found that
heparin-ciated ePTFE grafts resulted in less intimal hyperplasia and less platelet deposition after implantation, compared
with noncoated control ePTFE grafts.It is widely accepted that an autologous vein graft is the
ideal bypass conduit in peripheral arterial bypass proce-
dures. However, nearly a third of patients who undergo
peripheral arterial reconstructive operations do not have
adequate or available autologous vein graft, as a result of
either previous vein harvest or poor vein quality.1 Under
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doi:10.1016/j.jvs.2004.01.0461322such circumstances surgeons may have to rely on prosthetic
grafts, such as expanded polytetrafluoroethylene (ePTFE)
grafts, as an alternative conduit in arterial bypass proce-
dures.
Clinical outcomes with prosthetic grafts in peripheral
arterial reconstruction are generally inferior to those with
autologous vein bypass grafts, in part because of anasto-
motic neointimal hyperplasia.2 No doubt the strategy to
reduce anastomotic neointimal hyperplasia after prosthetic
bypass surgery is critically important to improve the clinical
outcome of vascular reconstruction.
One pharmacologic agent that has received wide re-
search focus as a means to reduce neointimal hyperplasia is
heparin, which is a mucopolysaccharide found in most
tissues. Heparin inhibits thrombin and activated factors IX,
X, XI, and XII, which are involved in the conversion of
prothrombin to thrombin, thereby reducing thrombin for-
mation. In addition, heparin has a potent antiproliferative
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effect is independent of its anticoagulant activity.3,4 Its
inhibitory effect on SMCs is mediated in part through
interactions with cell receptors, growth factors, adhesion
molecules, and proteinase inhibitors.5 In models of endo-
thelial denudation in the rat, sustained heparin infusions
decreased neointimal thickening by 40% to 50%.3,4,6,7 Our
laboratory previously demonstrated that local infusion of
heparin in aortoiliac bypass grafting significantly reduced
anastomotic neointimal hyperplasia in a baboon model.8
We also recently reported the benefit of heparin-coated
stents in reducing neointimal hyperplasia after iliac and
carotid artery placement in baboons.9,10
The objective of this study was to assess the effect of
heparin-coated PTFE grafts on neointimal hyperplasia after
prosthetic arterial reconstruction. We hypothesized that
the coating of a PTFE graft with heparin would provide a
biocompatible surface for the graft that limits anastomotic
neointimal hyperplasia. This study quantitatively analyzed
the neointimal thickness, neointimal area, and cell prolifer-
ation in the heparin-coated ePTFE grafts and uncoated
control grafts after aortoiliac reconstruction in a baboon
model.
MATERIAL AND METHODS
Heparin coating of ePTFE grafts. Standard ePTFE
grafts (internal diameter, 4 mm; length, 5 cm; Gore-Tex;
W. L. Gore and Associates, Flagstaff, Ariz) were used in our
study for heparin coating. The luminal surface of the graft
was first coated with the Carmeda bioactive surface, fol-
lowed by sequential polymer layered coating. The next
layer was polyethyleneimine (PEI) cross-linked with glutar-
aldehyde. This provided a positively charged surface on
which dextran-sulfate was ionically bound. On the nega-
tively charged dextran sulfate layer, another layer of PEI
was ionically bound. This second PEI layer provided a free
amino group, which was used to bind heparin through an
aldehyde group on the heparin. The heparin was modified
to contain the free aldehyde moiety with the technique
described previously.11,12 With this single-point attach-
ment method the heparin active site was available for bind-
ing anti-thrombin III (AT-III) and contained catalytic
function. The grafts were sterilized with ethylene oxide.
The post–ethylene oxide sterilization heparin activity and
concentration were approximately 53 pm AT-III uptake/
cm2 and 15 mg/cm2, respectively. These graft preparation
procedures were competed at W. L. Gore & Associates.
Platelet deposition in an exteriorized arteriovenous
shunt model. Platelet deposition was analyzed with an
exteriorized femoral arteriovenous shunt system, which was
surgically established in five baboons. This method of plate-
let deposition analysis has been well-characterized in our
laboratory.13,14 In brief, this ex vivo shunt system consists
of two 5-cm lengths of silicone rubber tubing (3.0-mm
diameter). Blood flow, established by connecting the two
silicone rubber shunt segments, was adjusted to 100 mL/
min. A PTFE segment was interposed between the arms of
the permanent arteriovenous shunt. Platelet deposition wasmeasured in real time with scintillation camera imaging of
indium 111–labeled platelets. Autologous baboon platelets
were labeled with 1 mCi of indium oxide (111In) and
reinjected at least 1 hour before imaging, when 111In-
labeled platelets were functionally normal. Gamma camera
images of vascular grafts were acquired continuously and
separately for 4 hours at 10-minute intervals, with a GE
400T scintillation camera (General Electric, Milwaukee,
Wis). The data were stored and analyzed on a Medical Data
System A3 Computer. A medium-energy collimator was
placed close to the animal. Measurements of 111In activity
were corrected for background activity.
Activity of a 5-mL whole blood standard was also
determined. The activity of the blood standard was also
corrected for the small fraction of circulating nonplatelet
radioactivity, to give platelet-associated 111In activity per
milliliter of whole blood. The total numbers of deposited
platelets in the heparin-coated or control grafts were calcu-
lated by dividing the deposited platelet activity (counts per
minute) by the circulating blood activity (counts  min-
utes1mL1) and multiplying by the circulating platelet
count (platelets per milliliter). The results were expressed as
platelets deposited per 1 cm of vascular graft. Platelet
deposition was analyzed between heparin-coated ePTFE
grafts and noncoated control grafts.
Aortoiliac bypass graft model in baboons. Eight
male baboons (Papio cynocephalus) weighing 9.4 to 13.3 kg
(mean, 12.9 kg) were used in the study. All animals had
been quarantined and observed to be disease-free for at
least 90 days. All procedures and care were performed in
accordance with the Guideline for the Care and Use of
Laboratory Animals (National Institutes of Health Publ.
No. 80-23, revised 1985) and the Food and Drug Admin-
istration Good Laboratory Practice for Non-clinical Labo-
ratory Studies Regulations (21 CFR, Part 58). Prophylactic
cefazolin (1 g; Kefzol; Marsam Pharmaceuticals, Cherry
Hill, NJ) was administered intravenously. Animals were
given thiopental sodium (10 mg/kg) intravenously (Pen-
tothal; Abbott Laboratories, North Chicago, Ill). Endotra-
cheal intubation was performed, and anesthesia was main-
tained with 1% isoflurane (Rhone-Poulenc, Bristol,
England). All animals received intravenous heparin (100
U/kg) at the time of the operation. Bilateral aortoiliac
bypass grafting was performed, with heparin-coated ePTFE
grafts placed on one side and noncoated control grafts
placed on the contralateral side, in a baboon model, as
previously described.8,15 Heparin-coated versus control
grafts were randomly alternated between right and left
aortoiliac segments (Fig 1). No anticoagulant medications
were administered postoperatively. Animals were killed and
the grafts harvested at 4 weeks for analysis.
Histologic and morphometric analysis. Bromode-
oxyuridine (BrdU; Sigma, St Louis, Mo), 50 mg/kg dis-
solved in 50 mL of normal saline solution, was adminis-
tered subcutaneously 24 hours before death at 28 days.
Grafts and adjacent 3-cm segments of attached vessel at
each anastomosis were harvested and fixed in 10% buffered
formalin (Baxter Diagnostics, McGaw Park, Ill). After fix-
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the midpoint between the heel and toe of each anastomosis
at a distance of 2 mm from the heel of each anastomosis and
at 5-mm intervals along the entire graft length. Five-micron
sections were cut and stained with hematoxylin-eosin and
Verhoeff-Masson stains. Cell ingrowth overlying the lumi-
nal surface of the graft adjacent to the anastomosis was
considered graft neointima, and cell proliferative tissue
overlying the internal elastic lamina of native vessels was
considered vessel neointima. Morphometric measurements
of the area of anastomotic neointima were performed with
computer image analysis software (Optimas; Bioscan, Ed-
monds, Wash) on a magnified image relayed from a micro-
scope-mounted video camera to a digitizing pad and video
monitor (Thomas Optical, Columbus, Ga), as previously
described.8,16 The graft and native vessel neointimal tissues
at the anastomoses were measured separately. Three tissue
blocks were generated between the heel and toe of each
anastomosis. From the three tissue blocks, mean values of
morphometric measurements and cell proliferation rates
were reported. All tissue samples were analyzed in a blinded
manner with respect to whether they were derived from
heparin-coated or control grafts.
Immunocytochemistry. The avidin-biotin complex
immunoperoxidase procedure (LSAB Kit; Dako, Carpen-
teria, Calif) was used to identify determinants that charac-
terized neointimal cell types and proliferating cells, as de-
scribed.8,16 In brief, immunostaining for -actin and factor
VIII–related antigen was performed to identify SMCs and
endothelial cells, respectively. Proliferating cells were iden-
tified with anti-BrdU monoclonal antibody (Dako). BrdU-
positive cells were quantified manually with a cell-counting
technique on a calibrated micrometer grid with microscopy
(400). In each field, all cells were counted, and the
Fig 1. Diagram of small-caliber expandable polytetrafluoroethyl-
ene (ePTFE) bilateral aortoiliac bypass grafting with end-to-side
anastomoses. Intervening segments of the distal aorta and proxi-
mal common iliac arteries were ligated. Heparin-coated ePTFE
graft was placed on one side, and non-coated ePTFE graft was
placed contralaterally and served as a paired internal control.number of positively stained cells was expressed as a per-
centage of total cells, to arrive at the BrdU index. A
minimum of 10 fields per section were quantified.
Statistical analysis. All statistical analysis was per-
formed with a statistical software program (SAS Institute,
Cary, NC). Comparisons of neointimal areas and cell pro-
liferation between the heparin-treated grafts and the con-
trol grafts were made with the Student t test (two-tailed)
for paired data. Comparisons of hematologic measure-
ments at various time points were made with analysis of
variance. Values are given as mean  SE. The results were
considered significant at P  .05.
RESULTS
Platelet deposition. There were significant differ-
ences in platelet deposition after 40 minutes between the
heparin coated and control grafts. Significant reduction in
platelet deposition was noted at all time points from 1 to 4
hours for heparin-coated grafts compared with noncoated
control grafts (P  .01; Table I).
Anastomotic neointimal hyperplasia. All animals
survived the duration of the study, and all aortoiliac grafts
remained patent at tissue harvesting. Measurable neointi-
mal hyperplasia was present at both proximal and distal
anastomoses in both the noncoated control grafts and the
heparin-coated grafts. SMCs were the major type of anas-
tomotic neointimal cells identified at -actin immunostain-
ing. Endothelial cells covered the surfaces of all of the
anastomotic neointimas as shown with factor VIII–related
antigen immunostaining. The results regarding anasto-
motic neointimal hyperplasia for the control and heparin-
coated grafts are shown in Table II. There was a significant
reduction of graft neointimal area at both proximal (0.26
0.11 mm2 ) and distal (0.29  0.14 mm2) anastomoses in
the heparin-coated grafts, as compared with proximal (0.56
 0.18 mm2) and distal (0.63 0.21 mm2) anastomoses in
the untreated control grafts (P  .05). In contrast, no
significant difference was noted in vessel neointimal area
and thickness between the two graft groups. Representative
sections of the proximal and distal anastomoses of the two
graft groups are shown in Figs 2 and 3, respectively.
Table I. Comparison of platelet deposition between
heparin-coated ePTFE grafts and noncoated control
ePTFE grafts (n  5 per group) using indium














1 0.64  0.04 0.10  0.009 .01
2 1.15  0.04 0.18  0.09 84 .01
3 1.59  0.08 0.39  0.11 75 .01
4 2.09  0.81 0.41  0.09 80 .01
ePTFE, Expandable polytetrafluoroethylene.
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eration was evaluated with BrdU incorporation staining.
SMCs were the major type of anastomotic neointimal cells
identified with -actin immunostaining. Endothelial cells
covered the surfaces of all of the anastomotic neointima, as
demonstrated with factor VIII–related antigen immuno-
staining. No significant difference in neointimal BrdU la-
beling index between proximal and distal anastomoses of
grafts was found. When comparing the cell proliferation of
graft neointima between the control and heparin-coated
grafts, the BrdU labeling index was significantly smaller (P
 .05; Table III) in the heparin-coated grafts (3.47 
0.43%) as compared with the control grafts (6.21% 
0.59%). However, the difference in BrdU labeling index in
the native vessel at the anastomoses was not significant
between the treated and control groups (5.73% 0.56% vs
4.81%  0.63%, respectively; P  .5). The data show that
heparin-coated grafts significantly reduced cell prolifera-
tion in the graft neointimal region, but exerted no signifi-
cant effects in the native neointimal tissues.
DISCUSSION
Although autologous vein graft is the ideal bypass
conduit in peripheral arterial bypass procedures, it is fre-
quently unavailable as a result of previous harvest or poor
vein quality in many patients who undergo a peripheral
arterial bypass procedure. Many alternative bypass conduits
have received wide research focus with regard to their
thrombogenic propensity and patency rate after vascular
reconstruction. Among them, ePTFE graft is the most
commonly used alternative bypass conduit when an autol-
ogous vein graft is not available. In clinical studies, ePTFE
grafts have performed reasonably well in large and medium-
sized arteries, but have had limited success in vessels with
diameter less than 6 mm, because of early graft occlu-
sion.17,18 The primary patency rates at 4 years for ePTFE
infrapopliteal grafts and aortocoronary grafts are only 12%
and 14%, respectively.19-21 Early graft occlusion from thro-
mobosis and late graft failure from neointimal hyperplasia
are two major challenges in small-caliber prosthetic vascular
reconstruction.
Neointimal hyperplasia is a complicated cellular and
molecular response to mechanical vascular injury. This
Table II. Effects of heparin-coated ePTFE grafts on








Graft neointima 0.56  0.18 0.26  0.11 .03 (NS)
Vessel neointima 0.65  0.15 0.61  0.13
Distal anastomosis
Graft neointima 0.63  0.21 0.29  0.14 .03 (NS)
Vessel neointima 0.48  0.15 0.59  0.13
ePTFE, Expandable polytetrafluoroethylene.response is characterized by SMC proliferation, migration,
and extracellular matrix production, with the final result
being vessel wall thickening and luminal narrowing. In
addition, this complex event may be accelerated in part as a
consequence of factors related to compliance mismatch,
endothelial dysfunction, ongoing platelet deposition,
monocyte recruitment, and chronic inflammatory reac-
tions. Therefore new strategies that target these pathways
may ultimately improve patency rates for small-caliber
ePTFE grafts in human beings.
Our current understanding with regard to the patho-
genesis of intimal hyperplasia is largely based on experimen-
tal models of balloon denudation injury, surgical endarter-
ectomy, and prosthetic bypass grafting. These experimental
evaluations of intimal hyperplasia have been studied exten-
sively in small animal models such as rats and rabbits.
Studies of intimal hyperplasia in larger primate animal
models, in contrast, are considerably scarce, but they may
have greater relevance to recurrent stenosis seen in the
clinical setting. This is due in part to the similar vessel
architecture and hemodynamics of the primate model com-
pared with human beings. The present study examined the
short-term platelet deposition of small-caliber heparin-
coated ePTFE grafts and the patency rate after aortoiliac
bypass graft in baboons, which exhibit a high degree of
genetic similarity with human beings. Platelet deposition
was analyzed by measuring 111In-radiolabeled platelet ac-
tivity, and neointimal hyperplasia was assessed with mor-
phometric analysis, which provided a detailed comparison
of the vessel wall architecture with respect to the intimal
and medial thickness.
We found that heparin-coated ePTFE grafts resulted in
reduced platelet deposition, compared with noncoated
control grafts. The thromboresistant mechanisms of hepa-
rin relate to its interaction with AT-III, resulting in AT-
heparin complex, which accelerates the inactivation of
thrombin and other coagulation factors.20 The formation
of an AT-heparin complex inhibits heparin-induced platelet
aggregation.22 Similar thromboresistant benefits of heparin
surface coating in reducing platelet activation and deposi-
tion have been demonstrated in various clinical devices,
including hemodialysis filters and intravascular stents, and
cardiopulmonary bypass circuitry.23-25
Table III. Effect of heparin-coated ePTFE grafts on











(BrdU%) 6.21  0.59 3.47  0.43 .05
Vessel neointima
(BrdU%) 4.81  0.63 5.73  0.56 NS
ePTFE, Expandable polytetrafluoroethylene; BrdU, bromodeopyuridine.
JOURNAL OF VASCULAR SURGERY
June 20041326 Lin et alOur study also showed that heparin-coated ePTFE
grafts resulted in significantly less anastomotic neointimal
hyperplasia, compared with noncoated grafts, as evidenced
by reduced cell proliferation and medial thickness. The
antiproliferative activity of heparin has been proven in
baboon, human, rat, and bovine SMC cultures.26,27 Ad-
ministration of heparin in vitro inhibits SMC proliferation
by inhibiting DNA synthesis and by limiting the transcrip-
tion gene necessary for cell passage from G0 through G1
and into the S phase.28,29
Research investigations have also focused on other
possible mechanisms by which heparin inhibits neointimal
proliferation. For example, the antiproliferative properties
of heparin may in part be mediated through inhibition of a
second messenger pathway, resulting in proto-oncogene
expression in cell cycling.30 Heparin not only inhibits in-
tracellular protein kinase activity during signal transduc-
tion,31 it also downregulates transcription activator pro-
Fig 2. Neointimal hyperplasia at proximal anastomoses.
anastomosis of untreated expandable polytetrafluoroeth
heparin-coated ePTFE graft (treated). L, Lumen; N, n
original magnification 40).
Fig 3. Neointimal hyperplasia at distal anastomoses. C
anastomosis of untreated expandable polytetrafluoroe
heparin-coated ePTFE graft (treated). L, Lumen; N, n
original magnification 40)teins.32 Moreover, it can modulate the function and
expression of numerous growth factors. Heparin can in-
hibit basic fibroblast growth factor–mediated growth re-
sponses of both endothelial and smooth muscle cells, and
downregulate basic fibroblast growth factor expression in
the wall of injured arteries.33 Heparin also inhibits epider-
mal growth factor receptor expression, and potentiates the
inhibitory properties of transforming growth factor- by
releasing it from a carrier protein.34,35 In addition, heparin
selectively inhibits the production of certain proteases crit-
ical for degrading extracellular matrix, which can diminish
cellular proliferation. These proteases include tissue-type
plasminogen activator, interstitial collagenase, stromelysin,
and gelatinase.36 All things considered, heparin has a cru-
cial role in modulating SMC migration and neointimal
proliferation via a complex biochemical and cellular cascade.
We previously reported the beneficial effect of heparin
in improving graft patency in small-caliber ePTFE bypass
gens are blue; elastin is black; others are red. A, Proximal
(ePTFE) graft (control). B, Proximal anastomosis of
ima; G, ePTFE graft material. (Verhoeff-Masson stain;
ens are blue; elastin is black; others are red. A, Distal
e (ePTFE) graft (control). B, Distal anastomosis of
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osmotic pump attached to the ePTFE graft after aortoiliac
bypass significantly reduced anastomotic neointimal hyper-
plasia. We also reported similar improved patency rates in
heparin-coated balloon-expandable stents compared with
noncoated stents after carotid and iliac artery placement in
baboons.9,10 Although these antiproliferative properties of
heparin in animal experiments represent potential treat-
ment strategies for recurrent stenosis, these beneficial ef-
fects of heparin have not been demonstrated consistently in
clinical trials of coronary balloon angioplasty.37,38 More-
over, the systemic infusion of heparin failed to reduce
intimal hyperplasia in a baboon angioplasty model, even at
concentrations previously effective in inhibiting baboon
SMC proliferation in culture.39 Several explanations may
account for the observed disparity in heparin effects, in-
cluding variations in heparin preparation, differences in
route and duration of heparin delivery, varying degrees of
arterial injuries, and interspecies differences in SMC prolif-
eration. In human beings and primates, the therapeutic
heparin dose for inhibiting SMC proliferation may be
quantitatively increased compared with the heparin re-
quirement in nonprimate smaller animals.
In summary, small-caliber heparin-coated ePTFE grafts
result in less platelet deposition after implantation in an
exteriorized femoral circulation in baboons, when com-
pared with noncoated grafts. In addition, heparin-coated
grafts inhibited SMC proliferation and anastomotic neoin-
timal hyperplasia at 4 weeks after aortoiliac bypass grafting,
compared with noncoated grafts. Our results suggest that
small caliber heparin-coated ePTFE grafts may represent a
useful therapeutic strategy to improve graft patency in
small-diameter prosthetic vascular reconstruction.
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